Search results
Showing 1 to 4 of 4 results for lebrikizumab
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)
Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.
Lebrikizumab for treating atopic dermatitis in children [TSID12133]
Topic prioritisation
Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]
Topic prioritisation
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.